Cellebrite Q2: This 33% Selloff Looks Like An Overreaction

Cellebrite DI Ltd. experienced a 33% post-earnings drop, but I view this as an overreaction given its robust fundamentals. Q2 saw ARR and revenue growth miss guidance, management transition, and slower-than-expected Inseyets conversions, but core products and retention remain strong. CLBT maintains high gross margins (80%+), strong free cash flow (28%), and guides for high-teens revenue growth despite execution risks and rising stock-based compensation.